ArticleInternational journal of women's health2025
Screening for Cervical Intraepithelial Lesions with TCT and HPV DNA: A Triage Strategy.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the value of the ThinPrep cytology test (TCT) combined with human papillomavirus (HPV) DNA detection in the screening and triage of cervical lesions. Methods: A total of 1671 patients with cervical inflammation or lesions who underwent colposcopy and biopsy between April 2020 and December 2022 were analyzed. The data included TCT, HPV DNA, and pathological findings. Results: The incidence of high-grade squamous intraepithelial lesions (HSILs) or above significantly increased with TCT severity: 25.9% in the negative for intraepithelial lesion or malignancy (NILM) group, 39.4% in the atypical squamous cells of undetermined significance (ASCUS) and low-grade SIL (LSIL) groups, and 76.5% in the HSIL+ group (P<0.001 for all pairwise comparisons). The incidence also varied significantly by HPV status: 58.2% in the HPV 16 or 18 group, 28.6% in the other high-risk groups, and 17.6% in the low-risk and negative groups (P<0.001 for all pairwise comparisons). Multivariate analysis revealed independent risk factors for HSIL+: younger age (OR=0.972), HSIL and above cytology (OR=10.154), ASCUS and LSIL cytology (OR=2.250), HPV 16/18 infection (OR=8.061), and other high-risk HPV infections (OR=2.578). Patients with concurrent HPV 16/18 infection and HSIL or above cytology presented a substantially elevated risk (OR=41.517). Among the cohort, 35 cases of cervical squamous cell carcinoma were identified. Conclusion: TCT combined with HPV DNA testing provides an effective strategy for risk stratification in cervical screening. Our findings support that patients with HPV16 or 18 should be referred directly for colposcopy, and patients with other high-risk HPV types and TCT results of ASCUS and above are also recommended for colposcopy referrals. These referral suggestions warrant further validation in larger, multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.